Stallergenes SA

Antony, France

Stallergenes SA

Antony, France
SEARCH FILTERS
Time filter
Source Type

Patent
Stallergenes S.A. | Date: 2017-09-06

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.


The present invention concerns pollen allergen extracts, in particular ragweed (Ambrosia) pollen allergen extracts, containing reduced amounts of copper-binding-like proteins in order to minimize the risk of toxicity, including induction of angioedema, of those allergen extracts. The invention also relates to methods of preparing pollen allergen extracts containing reduced amounts of copper-binding-like proteins.


Moingeon P.,Stallergenes SA
Journal of Allergy and Clinical Immunology: In Practice | Year: 2013

Sublingual immunotherapy (SLIT) is established as a safe and efficacious treatment for patients with type I respiratory allergies. The ability of SLIT to elicit antigen (allergen)-specific tolerance is linked to the peculiar biology of oral antigen-presenting cells. In the absence of danger signals, Langerhans cells, myeloid dendritic cells, and macrophages located in oral tissues, tonsils, and draining cervical lymph nodes are biased toward the induction of TH1 and IL-10-producing CD4+ regulatory T cells, thus supporting tolerance as opposed to inflammation. Sublingual administration does not lead to any detectable systemic exposure of intact allergens nor to IgE neosensitization. Oral tissues contain limited numbers of mast cells located in submucosal areas, thereby explaining the well-established safety profile of SLIT, with mostly local but rare systemic reactions. The induction of CD4+ regulatory T cells and blocking anti-inflammatory IgGs or IgAs are considered important for tolerance induction after SLIT. Specific molecular signatures associated with tolerogenic dendritic cells were recently reported during the onset of SLIT efficacy in the peripheral blood of patients exhibiting clinical benefit. Collectively, these observations confirm the induction of strong allergen-specific suppressive/tolerogenic immune responses during SLIT and pave the ground for the identification of biomarkers of efficacy. Practical implications of this emerging scientific knowledge are presented (1) to support the rational design of second-generation sublingual vaccines based on purified allergens, vector systems and/or adjuvants and (2) to help the clinician in decision making during his/her practice. © 2013 American Academy of Allergy, Asthma & Immunology.


Patent
Stallergenes S.A. | Date: 2013-08-05

The present invention notably concerns a novel major allergen from ragweed pollen, named Amb a X, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention. The invention also concerns uses of said polypeptides, in particular for diagnosing and preventing or treating an allergy.


Patent
Stallergenes S.A. | Date: 2014-02-05

The present invention notably concerns a novel major allergen from ragweed pollen, named Amb a X, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention. The invention also concerns uses of said polypeptides, in particular for diagnosing and preventing or treating an allergy.


Patent
Stallergenes Sa | Date: 2015-01-07

The present invention concerns C1q for use for treating allergy and/or asthma. The invention also relates to a pharmaceutical composition comprising C1q and at least one allergen and to products comprising C1q and at least one allergen as a combined preparation for use for treating allergy and/or asthma.


Patent
Stallergenes S.A. | Date: 2012-04-06

The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.


The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.


The present invention concerns the use of immunoglobulins of IgG_(1 )type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.


The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.

Loading Stallergenes SA collaborators
Loading Stallergenes SA collaborators